Evidence map›Paper›PMID 31429175›Full record

ArticleJournal of evaluation in clinical practice2020

Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions.

Bo Zhang, Wei Liu, Stephenie C Lemon, Bruce A Barton, Melissa A Fischer, Colleen Lawrence, Elizabeth J Rahn, Maria I Danila, Kenneth G Saag, Paul A Harris and 1 more

Abstract read
In one paragraph

Article in Journal of evaluation in clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo ZhangDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts.ORCID https://orcid.org/0000-0003-1574-198X
Wei LiuSchool of Management, Harbin Institute of Technology, Harbin, Heilongjiang, China.
Stephenie C LemonDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts.
Bruce A BartonDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts.
Melissa A FischerDepartment of Internal Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Colleen LawrenceVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.
Elizabeth J RahnDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.
Maria I DanilaDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.
Kenneth G SaagDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.
Paul A HarrisDepartment of Biomedical Informatics and Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Jeroan J AllisonDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts.

Funding

University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
Strengthening Translational Research in Diverse Enrollment (STRIDE)U01TR001812 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ALLISON, JEROAN J, HARRIS, PAUL A. · 2016 to 2020
$5.0M
University of Massachusetts Center for Clinical and Translational ScienceKL2TR001455 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIEFE, CATARINA I. · 2015 to 2024
$5.0M
AlcHepNet DCC UMMSU24AA026968 · NIAAA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BARTON, BRUCE A · 2018 to 2023
$4.4M
University of Massachusetts Center for Clinical and Translational ScienceTL1TR001454 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LEWIS, BRIAN C · 2015 to 2024
$3.6M
National Natural Science Foundation of China 11601106National Natural Science Foundation of China 91646106NCATS NIH HHS KL2 TR001455NCATS NIH HHS TL1 TR001454NCATS NIH HHS U01 TR001812NCATS NIH HHS UL1 TR001453NIAAA NIH HHS U24 AA026968NIH HHS 5 U01 TR001812NIH HHS 5 U01 TR001812NIH HHS KL2TR01455NIH HHS TL1TR01454NIH HHS U24 AA026968NIH HHS UL1TR001453University of Massachusetts Center for Clinical and Translational Science KL2TR01455University of Massachusetts Center for Clinical and Translational Science TL1TR01454University of Massachusetts Center for Clinical and Translational Science UL1TR001453
6 · The paper itself

Abstract

objectiveTo discuss the study design and data analysis for three-phase interrupted time series (ITS) studies to evaluate the impact of health policy, systems, or environmental interventions. Simulation methods are used to conduct power and sample size calculation for these studies.

methodsWe consider the design and analysis of three-phase ITS studies using a study funded by National Institutes of Health as an exemplar. The design and analysis of both one-arm and two-arm three-phase ITS studies are introduced.

resultsA simulation-based approach, with ready-to-use computer programs, was developed to determine the power for two types of three-phase ITS studies. Simulations were conducted to estimate the power of segmented autoregressive (AR) error models when autocorrelation ranged from -0.9 to 0.9 with various effect sizes. The power increased as the sample size or the effect size increased. The power to detect the same effect sizes varied largely, depending on testing level change, trend changes, or both.

conclusionThis article provides a convenient tool for investigators to generate sample sizes to ensure sufficient statistical power when three-phase ITS study design is implemented.

Indexed as

Health PolicyResearch DesignComputer SimulationHumansInterrupted Time Series AnalysisSample Sizeinterrupted time seriespolicy evaluationpowerquasi-experimental designsample size calculationsegmented regression

Identifiers

PMID31429175
PMCPMC7028460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.